UT MD Anderson and Nature to co-host conference on next-generation cancer therapeutics
In-person conference runs Oct. 6-8, 2026, with registration open until Oct. 5, 2026
Topics include next-generation cancer therapeutics and immunotherapies, protein modulators, emerging platforms and artificial intelligence models
HOUSTON, SEPTEMBER 15, 2026 ― The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics, highlighting advances in...
CPRIT awards UT MD Anderson over $19 million for cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded over $19 million from the Cancer Prevention and Research Institute of...
CPRIT awards MD Anderson over $29 million for prevention efforts, cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded over $29 million from the Cancer Prevention and Research Institute of...
Allison Institute’s third annual scientific symposium highlighted by panel discussion with five Nobel laureates
Sessions focused on the latest advances in cancer vaccines, immunotherapy and immunology research
Symposium featured a panel discussion with five Nobel laureates, moderated by TIME Senior Health Correspondent Alice Park
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium, “The Multiverse of Mechanistic Processes Impacting Immunity,” on Oct. 24 at the TMC3 ...
Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance
Study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation
These nerve injuries drive...
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained...
CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of Texas...
AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress...
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life...
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other DNA...